Investment Rating - The report maintains a "Strong Buy" investment rating for the company [3][7]. Core Insights - The company achieved a revenue of 12.261 billion CNY in 2024, representing a year-on-year growth of 21.3%, and a profit of 4.372 billion CNY, up 33.4% year-on-year [1][2]. - The sales revenue from innovative drugs and collaborative products reached 9.477 billion CNY in 2024, a 38.1% increase, accounting for 77.3% of total revenue [7]. - The company has shown strong cost control, with a gross margin of 91% in 2024, an increase of 1.2 percentage points year-on-year [7]. - The company is actively pursuing global collaborations, enhancing its competitive edge, with significant partnerships established in 2024 [7]. Financial Data and Valuation - The company’s projected revenues for 2025-2027 are 13.714 billion CNY, 15.395 billion CNY, and 17.378 billion CNY, with respective year-on-year growth rates of 12%, 12%, and 13% [2][9]. - The projected net profits for 2025-2027 are 4.588 billion CNY, 5.152 billion CNY, and 5.930 billion CNY, with growth rates of 5%, 12%, and 15% respectively [7][9]. - The company’s PE ratios for 2025-2027 are projected to be 24.6, 21.9, and 19.1 [9]. Shareholder Information - The total market capitalization of the company is 120.5 billion HKD, with a total share capital of 5,936 million shares [3]. - The major shareholder, Sunrise Investment Advisors Limited, holds a 65.7% stake in the company [3]. Performance Metrics - The company’s return on equity (ROE) is reported at 15.2% for 2024, with a projected increase to 15.4% by 2027 [9]. - The asset-liability ratio is notably low at 9.4% in 2024, indicating strong financial stability [9].

Group 1: A-share Market Overview - The A-share market experienced narrow fluctuations in the morning, with major indices declining [1][5] - The tourism sector saw significant gains, with an overall increase of over 4%, leading to a surge in stocks hitting the daily limit [5][4] - Key stocks in the tourism sector included Zhangjiajie, Emei Mountain A, Dalian Shengya, and Tianfu Culture Tourism, all reaching the daily limit [5] Group 2: New Stock Performance - The newly listed stock, Xidian Co., saw its price surge by over 260% during the morning session, with potential gains exceeding 60,000 yuan for investors who received a subscription [10][11] - Xidian Co. specializes in the research, development, production, and sales of semiconductor testing equipment, focusing on probe testing technology [11][12] - The company has become the largest probe station equipment manufacturer in mainland China, holding a 13% market share in the probe station equipment market as of 2019 [12] Group 3: Hong Kong Market Overview - The Hong Kong market showed overall fluctuations, with stocks like Weishi Jiajie experiencing a price increase of over 19% [3][13] - Weishi Jiajie reported a revenue of 89.086 billion HKD for the fiscal year 2024, with a net profit attributable to shareholders of 1.052 billion HKD [16] - The company's AI business revenue grew by 42%, while cloud computing revenue increased by 28%, indicating strong growth in these sectors [16]

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 23.82 [8][9]. Core Insights - The company reported a revenue of RMB 12.261 billion for 2024, representing a year-on-year growth of 21.3%, and a net profit of RMB 4.372 billion, up 33.4% year-on-year. The revenue from innovative drugs reached RMB 9.477 billion, growing 38.1% year-on-year, and accounting for 74% of total revenue, which aligns with expectations [1][2]. - The growth in revenue is driven by strong performance in oncology and anti-infection segments, with revenues of RMB 8.122 billion and RMB 1.464 billion respectively, reflecting increases of 31.7% and 15.4% year-on-year. The gross margin improved to 91%, while the R&D expense ratio increased to 22%, indicating ongoing investment in innovation [2][3]. - The company has seven innovative drugs and nine indications included in the national medical insurance catalog as of 2024, with over 40 new molecular entities in more than 60 clinical trials. The company completed three license-in agreements in 2024, generating R&D expenses of RMB 247 million [3][4]. Summary by Sections Financial Performance - For 2024, the company achieved revenues of RMB 12.261 billion, with a year-on-year growth of 21.35%. The net profit for the same year was RMB 4.372 billion, reflecting a growth of 33.39% [7][19]. - The projected net profits for 2025 and 2026 are RMB 4.400 billion and RMB 4.179 billion respectively, with an expected EPS of RMB 0.74 for 2025 [5][19]. Research and Development - The company has a robust pipeline with 40 new molecular entities and over 60 clinical trials ongoing. Key drugs like Amatinib are expected to generate significant sales, projected to reach RMB 6 billion by 2025 [4][5]. - The company is actively expanding into autoimmune diseases and has multiple assets in development for skin diseases and kidney diseases [4][5]. Valuation - The company is valued at HKD 1,414 billion, with the innovative drug segment valued at HKD 1,378 billion and the generic drug segment at HKD 36 billion. The target price reflects an increase from the previous valuation of HKD 22.28 [5][9].

Financial Performance - The company reported revenue of approximately RMB 12.261 billion for the year ending December 31, 2024, representing a year-on-year growth of approximately 21.3%[4] - Profit for the same period was approximately RMB 4.372 billion, an increase of about 33.4% compared to the previous year[15] - Basic earnings per share were approximately RMB 0.74, an increase of approximately 33.3% compared to the previous year[4] - Revenue for the year ended December 31, 2024, reached RMB 12,260,814 thousand, a 21.4% increase from RMB 10,103,806 thousand in 2023[77] - Gross profit for 2024 was RMB 11,155,406 thousand, up from RMB 9,072,943 thousand in 2023, reflecting a significant growth in profitability[77] - Net profit for the year was RMB 4,371,825 thousand, representing a 33.4% increase compared to RMB 3,277,503 thousand in 2023[79] - The group's profit before tax rose to RMB 3,327,665,000 in 2024, compared to RMB 2,680,840,000 in 2023, reflecting a growth of 24.2%[90] Revenue Breakdown - Sales revenue from innovative drugs and collaborative products reached approximately RMB 9.477 billion, an increase of approximately 38.1% year-on-year, accounting for about 77.3% of total revenue[4] - Revenue from the oncology segment was approximately RMB 8.122 billion, making up about 66.2% of total revenue[18] - The anti-infection segment generated revenue of approximately RMB 1.464 billion, contributing about 11.9% to total revenue[18] - The central nervous system segment reported revenue of approximately RMB 1.379 billion, representing about 11.3% of total revenue[18] - The metabolic and other diseases segment achieved revenue of approximately RMB 1.296 billion, accounting for about 10.6% of total revenue[18] Research and Development - Research and development expenses amounted to approximately RMB 2.702 billion, up approximately 28.8% year-on-year, representing about 22.0% of total revenue[4] - Over 60 clinical trials for innovative drugs are currently ongoing, with 8 new candidates entering clinical research stages during the reporting period[37] - The company has published multiple research findings on ShengLuoLai® in prestigious journals and conferences, focusing on its mechanism of action and clinical studies[33] Product Approvals and Developments - The company received clinical trial approval for the innovative drug HS-10501, intended for the treatment of type 2 diabetes and adult obesity[6] - The innovative drug Amelot® received its third NDA acceptance from NMPA for use in NSCLC patients with specific mutations[9] - The innovative drug Amelotin® has been approved for three indications and was successfully included in the 2024 National Medical Insurance Directory[21] - The product XinYue® (Inalizumab injection) received NMPA approval for treating adult patients with AQP4 antibody-positive NMOSD on March 14, 2022, and was included in the national medical insurance catalog in January 2023[25] - HS-20093, a B7-H3 targeted ADC, has entered Phase III clinical trials for small cell lung cancer and has shown strong anti-tumor activity in preliminary studies[40][41] Licensing Agreements - A licensing agreement was established with Zhuhai Pumis Biotechnology Co., granting the company exclusive rights to develop and commercialize HS-20117 globally[6] - The company entered into a global exclusive licensing agreement with Merck Sharp & Dohme LLC for the development of the investigational GLP-1 receptor agonist HS-10535[13] - The company has entered into a licensing agreement with Promis to develop and commercialize the bispecific antibody HS-20117 globally, currently in Phase I clinical trials[49] - The company has secured a licensing agreement with LUPON Pharmaceuticals for HS-10561, a BTK inhibitor, with clinical trials for chronic spontaneous urticaria expected to commence in February 2025[51] Corporate Governance and Sustainability - The company maintained an MSCI ESG rating of AA and was included in the S&P Global Sustainable Development Yearbook 2025, ranking first in the Chinese pharmaceutical industry[13] - The company plans to continue reviewing and enhancing its corporate governance practices to ensure compliance with the corporate governance code[110] - The audit committee, consisting of three independent non-executive directors, reviewed the audited performance for the year ending December 31, 2024[112] Cash Flow and Financial Position - The group reported a net cash inflow from operating activities of RMB 3.862 billion for the year ending December 31, 2024[62] - As of December 31, 2024, the group had cash and bank deposits totaling RMB 22.622 billion, an increase from RMB 22.435 billion as of December 31, 2023[63] - The group's asset-liability ratio was approximately 9.4% as of December 31, 2024, a decrease from 21.9% as of December 31, 2023[63] - Total assets less current liabilities increased to RMB 28,962,631 thousand in 2024 from RMB 26,176,230 thousand in 2023, indicating a stronger financial position[81] Dividends and Shareholder Returns - The declared final dividend for 2023 was RMB 768,760,000, significantly higher than RMB 268,852,000 for 2022, representing a 186.5% increase[96] - The company announced a final dividend of HKD 0.1353 per share for the year ending December 31, 2024, down from HKD 0.1422 in 2023[115] - The total dividend for the year 2024, including the interim dividend, amounts to HKD 0.3363 per share[115]

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index within the next six months [12]. Core Insights - The competition in the third-generation EGFR-TKI market is intensifying, with Tongyuan Kang entering the fray. Their drug TY-9591 has shown significant clinical benefits compared to Osimertinib in treating EGFR-mutant lung cancer with brain metastases [3][5]. - TY-9591 is a tyrosine kinase inhibitor (TKI) specifically developed for patients with EGFR-mutant lung cancer and brain metastases, demonstrating the ability to effectively cross the blood-brain barrier and irreversibly bind to EGFR mutations [4][6]. - The clinical trial results indicate that TY-9591 outperformed Osimertinib in terms of intracranial objective response rate (iORR), with significant statistical and clinical improvements across various patient subgroups [5][9]. Summary by Sections Industry Overview - The third-generation EGFR-TKI market is rapidly growing, with increasing patient numbers and a projected global sales figure for Osimertinib exceeding $6 billion by 2024 [7][9]. - There are currently seven third-generation EGFR-TKIs available in the domestic market, leading to heightened competition among manufacturers [10][11]. Company Insights - Tongyuan Kang's TY-9591 is the first and only drug in head-to-head clinical studies against Osimertinib to show significant superiority, with a trial involving 224 participants reflecting real-world mutation distribution [5][9]. - The safety profile of TY-9591 is favorable, with no new safety signals reported, and it utilizes deuterated technology to enhance brain penetration while reducing side effects [6][9].

Summary of Hansoh Pharmaceutical Conference Call Company Overview - **Company**: Hansoh Pharmaceutical - **Industry**: Pharmaceutical Key Points and Arguments - **Innovation Transformation**: Hansoh Pharmaceutical has significantly transformed into an innovative company, with innovative drug revenue expected to exceed 80% by 2025. Currently, 8 innovative drugs are listed and included in the medical insurance catalog, providing strong growth momentum for the company's performance [2][3] - **Ameitini Drug Performance**: Ameitini, a third-generation EGFR-TKI, has advantages in efficacy and safety, with multiple indications approved. It is expected to receive approval for postoperative adjuvant therapy in the first half of 2024, with peak sales projected to exceed 6.5 billion RMB [2][10] - **International Market Expansion**: The company actively expands overseas markets through licensing agreements, such as granting the oral GLP-1R agonist to Merck and ADCs B7H3 and B7H4 to GSK, generating substantial upfront payments and enhancing international visibility [2][5] - **Financial Position**: Hansoh Pharmaceutical has a strong cash reserve exceeding 20 billion RMB, supporting ongoing licensing transactions and the expansion of its innovative pipeline, as well as steady progress in early-stage R&D projects [2][6] - **Clinical Trials and Pipeline Progress**: The company has multiple ADC projects progressing well, with B7-H3 ADC entering Phase III trials for non-small cell lung cancer and BHH4 ADC starting Phase III trials for ovarian cancer [2][4] - **Revenue Projections**: Total revenue for 2024 is expected to be around 12 billion RMB, with innovative drug revenue exceeding 8 billion RMB. Peak sales for listed innovative drugs are anticipated to reach 15 billion RMB, while pipeline drugs could achieve peak sales of 15-16 billion RMB [2][18] - **Profit and Valuation Outlook**: Projected profit for 2025 is over 4.1 billion RMB, with a potential market capitalization of 130 billion RMB if valued at a 30x P/E ratio, indicating potential for historical highs [2][8][19] Additional Important Insights - **Sales Growth**: The company's internal operating revenue grew nearly 14% year-on-year in the first half of 2024, with innovative drug revenue accounting for 77% of total revenue [3] - **Market Dynamics**: The third-generation TKI market is expected to reach 15 billion RMB in 2024, with Ameitini's market share expected to grow significantly due to its competitive advantages [10][11] - **Clinical Development**: The company has several promising innovative drug pipelines in preclinical stages, including an oral GLP-1R agonist and dual-target ADCs, which are expected to lead to further overseas transactions [9] - **Upcoming Events**: Hansoh Pharmaceutical plans to hold a performance exchange and conference call next week, with expectations to meet or exceed the revenue guidance of 12 billion RMB for 2024 [21]

| | 国泰君安证券 | | --- | --- | | | GUOTAI JUNAN SECURITIES | 目 录 | | 每日报告回放（2025-03-13 09:00——2025-03-14 15:00） 2 | | | --- | --- | --- | |  | 事件点评：《通胀降温或为暂时，仍需警惕"滞胀交易"》2025-03-13 | 2 | |  | A 股策略观察：《外资交易热度抬升，杠杆资金延续流入》2025-03-14 | 3 | |  | 行业更新：煤炭《下行风险释放，4 月有望进入上升通道》2025-03-14 | 3 | |  | 行业专题研究：计算机《DeepSeek 重构算力基建长期价值的认知》2025-03-14 | 4 | |  | 行业首次覆盖：化学制剂《抗肿瘤疗法持续迭代，国产新药迎来突破》2025-03-13 | 5 | |  | 行业日报/周报/双周报/月报：环保《首批 CCER 登记，全国碳市场加速完善》2025-03-13 | 6 | |  | 行业深度研究：公用事业《从成长到红利，城燃行业价值重构》2025-03-13 | 7 | |  | ...

Group 1 - Investment Rating: "Recommended" for Shengyi Technology (600183.SH) [2][17] - Investment Rating: "Outperform" for AMC's involvement in real estate asset restructuring [9][12] - Investment Rating: "Outperform" for humanoid robot perception systems [19][21] Group 2 - Core View: AMC's accelerated involvement in real estate non-performing assets is a crucial method for mitigating industry risks, but successful cases are limited to high-quality projects with temporary liquidity issues [2][12] - Core View: Shengyi Technology is positioned as a leading domestic player in high-end CCL, with expected EPS growth from 0.73 yuan in 2024 to 1.37 yuan in 2026, driven by recovering demand and AI-related growth [2][17] - Core View: The humanoid robot market has significant potential, with perception systems being a core subsystem that integrates various sensors for environmental interaction [19][21] Group 3 - Summary of Real Estate Report: AMC's deep involvement in revitalizing the industry requires government support and management restructuring, with successful cases focusing on regionally high-quality projects [9][10] - Summary of Shengyi Technology Report: The company has a comprehensive product matrix and is expected to benefit from the recovery in downstream demand and AI-driven growth, with a projected PE of 40.5x for 2025 [2][17] - Summary of Humanoid Robot Report: The perception system, including 3D vision and tactile sensors, is essential for humanoid robots, indicating a substantial market opportunity as the technology matures [19][21]

Industry Investment Rating - The report assigns a "Leading" investment rating to the pharmaceutical industry, indicating an expectation of attractive performance relative to the benchmark index over the next 12 months [1]. Core Insights - The strong foundation project in healthcare is expected to create new opportunities in the medical device sector, with a focus on innovative drugs, prescription drugs, and CXO during the annual report season [1][4]. - The report highlights the potential benefits of the healthcare strong foundation project, which aims to enhance grassroots medical services and infrastructure, thereby driving growth in the medical device market [4][6]. - The report suggests that the pharmaceutical sector still has significant room for recovery, given the favorable policies expected to be implemented in the second half of 2025, alongside the current low valuations of the sector [4]. Summary by Sections Market Performance - The Hang Seng Index fell by 3.2% during the week of March 6-12, 2025, while the Hang Seng Healthcare Index decreased by 2.8%, ranking 10th among 12 industry indices [4][8]. - Sub-sectors such as biotechnology, life sciences tools and services, and pharmaceuticals experienced declines of 1.1%, 1.3%, and 1.6% respectively [4]. Investment Recommendations - The report recommends focusing on sub-sectors with potential for above-expectation performance, including innovative drugs, prescription drugs, and CXO [4]. - Specific companies highlighted for their growth potential include 康方生物 (CanSino Biologics), 信达生物 (Innovent Biologics), and 传奇生物 (Legend Biotech), which are expected to benefit from short-term catalysts and high growth [4][6]. - The report also emphasizes the importance of AI in healthcare, suggesting investment in companies with clear applications in health management [4]. Company Updates - 康方生物 has completed patient enrollment for its Phase III clinical trial of 卡度尼 (AK104) for high-risk liver cancer [6]. - 云顶新耀 has initiated the first human trial for its mRNA personalized cancer vaccine EVM16 [7]. - 翰森制药 received approval for a new indication for 阿美替尼 (Amehtinib) for non-small cell lung cancer [7]. - 中国生物制药's injection of 甲磺酸艾立布林 has been approved by the FDA for metastatic breast cancer treatment [7]. Valuation Overview - The report provides a valuation summary indicating that the pharmaceutical sector has a TTM P/E ratio of 11.3, while other sectors like life sciences tools and services have a TTM P/E of 7.3 [13].

Summary of Key Points from the Conference Call Industry or Company Involved - The conference call discusses the cryptocurrency market, particularly focusing on Bitcoin, and its relationship with traditional assets like gold and the stock market. It also touches on the Hong Kong stock market as a platform for global capital allocation. Core Points and Arguments Bitcoin as an Alternative Asset - Bitcoin has transitioned from being primarily driven by retail speculation to being influenced by institutional investment and U.S. dollar liquidity, showing a negative correlation with U.S. real interest rates [3][4][5] - The price of Bitcoin is highly correlated with mining costs, which increase with greater computational power [3][4] - Bitcoin's long-term annualized return can exceed 80%, but it also exhibits a volatility rate over 60%, posing challenges for institutional investors [5][6] Relationship with Gold - Gold prices are influenced by multiple factors, including central bank purchases, U.S. fiscal deficits, and market dynamics, with a mid-term target price of $3,100 to $3,200 [3][19] - Central bank gold purchases have altered the supply-demand dynamics in the gold market, particularly with China reducing U.S. Treasury holdings while increasing gold reserves [21][22] - The creditworthiness of the U.S. dollar significantly impacts gold prices, with high fiscal deficits undermining dollar credibility and pushing gold prices higher [23][24] Market Dynamics and Risks - Bitcoin faces risks from technological vulnerabilities, potential competition from superior cryptocurrencies, and significant sell-offs by large holders (whales) [8][9] - The correlation between Bitcoin and the Nasdaq index has strengthened since 2020, indicating that both are influenced by macro liquidity conditions [5][15] - The tightening of U.S. dollar liquidity is expected to support gold and Bitcoin prices in the near term [12] Hong Kong Stock Market - The Hong Kong stock market is positioned as a crucial platform for global capital allocation, with mechanisms like ETF cross-listing facilitating cross-border investments [35][36] - The market has seen a significant increase in cross-border investment activities, with a notable rise in the proportion of southbound capital [35][41] - The future of the Hong Kong market is expected to be shaped by its role as an international financial center, with ongoing developments in ETF products and cross-border investment channels [39][40] Other Important but Possibly Overlooked Content - The potential for AI technology to enhance productivity in various sectors, including logistics and transportation, is highlighted as a significant trend that could impact market dynamics [55] - The ongoing geopolitical tensions and their effects on gold demand and pricing are noted, with a focus on how these factors could influence investment strategies [28][29] - The historical context of gold price fluctuations and the factors leading to significant market corrections are discussed, providing insights into potential future trends [32][34] This summary encapsulates the key insights from the conference call, focusing on the cryptocurrency market, particularly Bitcoin, its relationship with gold, and the evolving role of the Hong Kong stock market in global capital allocation.